When should FDG‐PET be used in the modern management of lymphoma?

Positron Emission Tomography (PET) is a functional imaging technique that, combined with computerized tomography (PET‐CT), is increasingly used in lymphoma. Most subtypes accumulate fluorodeoxyglucose (FDG) and the increased sensitivity of PET‐CT, especially for extranodal disease, compared to CT, makes PET‐CT an attractive staging tool. The availability of a staging PET‐CT scan also improves the accuracy of subsequent response assessment. ‘Interim’ PET‐CT can be used to assess early response and end‐of‐treatment PET‐CT assesses remission. Clinical trials are currently seeking to establish whether the predictive value of PET‐CT can be successfully used to guide individual treatment to reduce toxicity and/or to improve outcomes. Standardized methods for performing and reporting PET have been developed in the context of trials. The role of PET in transplantation selection is currently evolving, as it appears to be more accurate and prognostic than CT. The role of FDG PET‐CT throughout the management course in patients with lymphoma is explored in this review, with areas discussed that may limit the use of PET‐CT imaging which clinicians should be familiar with to inform practice.